Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 1

5(62.5%)

Phase 2

2(25.0%)

Phase 3

1(12.5%)

8Total

Phase 1(5)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07174310Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Role: collaborator

NCT03100149Phase 2Active Not Recruiting

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

Role: collaborator

NCT04777331Phase 2Active Not Recruiting

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

Role: collaborator

NCT03043768Completed

Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease

Role: collaborator

NCT03336580Phase 1Terminated

A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis

Role: lead

NCT02630901Phase 1Completed

Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis

Role: lead

NCT02157714Phase 1Completed

Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease

Role: lead

NCT02458677Phase 1Completed

Single Ascending Dose Study of PRX003 in Healthy Subjects

Role: lead

NCT02095171Phase 1Completed

Single Ascending Dose Study of PRX002 in Healthy Subjects

Role: lead

All 9 trials loaded